공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

C5a 아나필라톡신 주화성 수용체 1(C5a 아나필라톡신 주화성 수용체, C5a-R, CD88, C5AR1) : 파이프라인 리뷰

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 363563
페이지 정보 영문 79 Pages
가격
US $ 3,500 ₩ 4,191,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,382,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,573,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


C5a 아나필라톡신 주화성 수용체 1(C5a 아나필라톡신 주화성 수용체, C5a-R, CD88, C5AR1) : 파이프라인 리뷰 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 79 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 각국에서의 C5a 아나필라톡신 주화성 수용체 1(또는 C5a 아나필라톡신 주화성 수용체, C5a-R, CD88, C5AR1) 치료제 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 동향, 임상시험 단계별 제품 일람, 주요 기업 프로파일, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

1. 목차

  • 서론
    • 분석 범위
  • C5a 아나필라톡신 주화성 수용체 1(C5a 아나필라톡신 주화성 수용체, C5a-R, CD88, C5AR1) 개요
  • 치료제 개발 상황
    • 임상시험 단계별
    • 치료 영역별
    • 증상별
  • 파이프라인 제품 개요
    • 후기 단계 제품
    • 초기 단계 제품
  • 각 기업에서 개발중인 치료제
  • 치료제 평가
    • 단일요법(Monotherapy)/결합제품(Combination Products)별
    • 작용기전별
    • 투여 방법별
    • 분자 종류별
  • 치료제 개발에 참여하고 있는 기업
    • AFFiRiS AG
    • ChemoCentryx, Inc.
    • Dompe Farmaceutici S.p.A.
    • Noxxon Pharma AG
  • 치료제 개요
    • CCX-168
      • 제품 개요
      • 작용기전
      • 연구개발(R&D) 진전 상황
    • DF-2593A
    • Drug to Antagonize C5aR for P
    • EP-67
    • NOXD-19
    • NOXD-20
    • Small Molecule to Target C5aR for Undisclosed Indication
    • Synthetic Peptide to Antagonize C5aR for Amyotrophic Lateral Sclerosis
    • Vaccine to Target C5a for Alzheimer's Disease
  • 휴지 상태인 프로젝트
  • 개발이 중지된 제품
  • 주목해야 할 최신 동향과 프레스 릴리스(총 15건)
  • 부록

2. 도표

LSH 16.08.03

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Indications, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Alsonex Pty Ltd, 2021
  • Pipeline by ChemoCentryx Inc, 2021
  • Pipeline by Dompe Farmaceutici SpA, 2021
  • Pipeline by Innate Pharma SA, 2021
  • Pipeline by MorphoSys AG, 2021
  • Pipeline by Prommune Inc, 2021
  • Pipeline by Teva Pharmaceutical Industries Ltd, 2021
  • Pipeline by Visterra Inc, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

According to the recently published report 'C5a Anaphylatoxin Chemotactic Receptor 1 - Drugs In Development, 2021'; C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production.

The report 'C5a Anaphylatoxin Chemotactic Receptor 1 - Drugs In Development, 2021' outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Musculoskeletal Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Autoimmune Disorders, Huntington Disease, Parkinson's Disease, Allergic Asthma, Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Bullous Pemphigoid, Chronic Urticaria Or Hives, Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hidradenitis Suppurativa, Inflammatory Bowel Disease, Inflammatory Pain, Lupus Nephritis, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Metastatic Cancer, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Motor Neuron Diseases, Neuroinflammation, Neuropathic Pain (Neuralgia), Pain, Periodontitis, Solid Tumor and Transplant Rejection.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
  • The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
  • Alsonex Pty Ltd
  • ChemoCentryx Inc
  • Dompe Farmaceutici SpA
  • Innate Pharma SA
  • MorphoSys AG
  • Prommune Inc
  • Teva Pharmaceutical Industries Ltd
  • Visterra Inc
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
  • ALS-205 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • avacopan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • avdoralimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DF-2593A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Antagonize C5aR for Periodontitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EP-67 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Antagonize C5AR1 for Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis and Transplant Rejection - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MOR-210 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PMX-205 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
  • C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 06, 2021: Innate Pharma to stop development of avdoralimab for Covid-19
  • Jul 06, 2021: ChemoCentryx announces filing of amendment to NDA submission and extension of the PDUFA review period for Avacopan in the treatment of ANCA-Associated Vasculitis
  • Jun 08, 2021: ChemoCentryx announces abstract on Avacopan in ANCA-Associated Vasculitis selected as one of the ten best abstracts at the ERA-EDTA Congress
  • May 06, 2021: ChemoCentryx announces results of FDA Advisory Committee Meeting on Avacopan in ANCA-associated vasculitis
  • Mar 02, 2021: Kissei seeks approval for C5aR inhibitor Avacopan in Japan
  • Feb 17, 2021: ChemoCentryx announces publication in The New England Journal of Medicine of results of the pivotal phase III ADVOCATE trial of Avacopan for the treatment of ANCA-associated vasculitis
  • Feb 10, 2021: I-Mab announces China NMPA clearance for phase 1 study of TJ210/MOR210 in patients with advanced solid tumors
  • Jan 25, 2021: I-Mab and MorphoSys announce first patient dosed in U.S. phase 1 study of TJ210/MOR210 in patients with advanced cancer
  • Dec 21, 2020: VFMCRP and ChemoCentryx provide topline results from ACCOLADE trial of Avacopan in C3 glomerulopathy including improved Estimated Glomerular Filtration Rate (eGFR)
  • Dec 21, 2020: ChemoCentryx and VFMCRP provide topline results from ACCOLADE trial of Avacopan in C3 Glomerulopathy including improved estimated Glomerular Filtration Rate (eGFR)
  • Nov 11, 2020: I-Mab announces preclinical data on differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
  • Nov 06, 2020: ChemoCentryx announces plenary session at ACR Convergence 2020 to highlight findings of ADVOCATE phase III trial in ANCA-associated vasculitis
  • Nov 03, 2020: VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
  • Oct 28, 2020: ChemoCentryx announces positive topline results of phase II AURORA clinical trial of Avacopan in the treatment of hidradenitis suppurativa (HS)
  • Oct 27, 2020: I-Mab to present preclinical data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q